海外の治験の状況「1」での検索結果
7748件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not recruiting
- Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy
- Urothelial Carcinoma
- Italy
- 2019-05-06
Not recruiting
- Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets
- HIV-1
- Spain, United States
- 2019-07-02
Not recruiting
- Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients
- Colorectal Cancer
- Italy
- 2019-08-22
Not recruiting
- Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas
- Neuroendocrine Carcinomas
- Italy
- 2019-09-04
Not recruiting
- LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib
- Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- Belgium
- 2019-12-09
Not Recruiting
- Cerebral hemodynamics after brachytherapy in pediatric patients with supratentorial low-grade astrocytoma or optic pathway glioma in patients with and without neurofibromatosis type I
- Y84.2 (ICD10) Radiological procedure and radiotherapy;D33.0 - Benign neoplasm: Brain, supratentorial;Q85.0 - Neurofibromatosis (nonmalignant);I67.9 - Cerebrovascular disease, unspecified
- Germany
- 2014-04-17
Not recruiting
- An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy
- Non-Squamous Non-Small Cell Lung Cancer;Non-Squamous Non-Small Cell Lung Cancer;Non-Squamous Non-Small Cell Lung Cancer;Non-Squamous Non-Small Cell Lung Cancer
- Belgium
- 2012-08-10
Not Recruiting
- A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)
- Hepatocellular Carcinoma;C22.0 - Malignant neoplasm: Liver cell carcinoma
- Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Norway, Philippines, Portugal, Romania, Spain, Sweden, Switzerland, Taiwan, Province of China, Thailand, United States
- 2012-05-09
Not Recruiting
- Clinical, open and multicentric phase II trial to evaluate the efficacy and safety of Bendamustine in combination with Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line therapy for the mulitple myeloma for patients with relapsed or non-responded patients in the 1st line therapy
- First relapsed or refractory multiple myeloma (including relapse after high dose chemotherapy followed by autologous stem cell transplantation) MedDRA version: 16.1 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Germany, Switzerland
- 2011-10-11
Not Recruiting
- A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992 50 mg once daily (BB) versus mFOLFOX7 alone as first-line therapy in patients with metastatic colorectal cancer. - Combination of BIBF 1120, BIBW 2992 and mFOLFOx7 as first-line therapy for colorectal cancer
- Metastatic colorectal carcinoma MedDRA version: 8.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer
- France, Germany, Spain
- 2006-11-16
Not Recruiting
- A multicenter randomized phase II trial to compare trastuzumab (Herceptin®) continuation or discontinuation in combination with 2nd-line chemotherapies after progression on a 1st-line chemotherapy combined with trastuzumab in patients with HER2 positive metastatic breast cancer (Treatment Beyond Progression, TBP) - PANDORA
- Metastacic breast cancer MedDRA version: 8.1 Level: LLT Classification code 10027475 Term: Metastatic breast cancer
- Bulgaria, Estonia, Hungary, Latvia, Lithuania
- 2006-08-14
Not Recruiting
- Randomized, open-label phase II study evaluating the safety and efficacy of Cetuximab plus modified FOLFOX - 6 versus modified FOLFOX - 6 alone as 2nd line therapy after progression on the 1st line treatment with Cetuximab + FOLFIRI in patients with metastatic colorectal cancer KRAS wild-type – TAGUS Study - TAGUS Study
- Colorectal cancer KRAS wild-type
- Portugal
- 2009-11-05
Not recruiting
- Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
- Renal Cell Carcinoma;Renal Cell Carcinoma;Renal Cell Carcinoma;Renal Cell Carcinoma
- Argentina, Australia, Brazil, Canada, Denmark, France, Germany, Hong Kong, Italy, Korea, Republic of, Mexico, Netherlands, Peru, Puerto Rico, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States
- 2009-04-24
Not Recruiting
- An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment - RAD001 and NETs, first line treatment
- Patients with neuroendocrine tumours MedDRA version: 9.1 Level: LLT Classification code 10057270 Term: Neuroendocrine carcinoma
- Italy
- 2009-04-01
Not Recruiting
- A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, INTERNATIONAL, MULTICENTER STUDY OF ORAL TAC 101 AS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA WHO RECEIVED SORAFENIB AS FIRST LINE THERAPY
- Advanced Hepatocellular carcinoma (HCC) MedDRA version: 9.1 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable
- Belgium, France, Germany, Greece, Italy, United Kingdom
- 2008-03-14
Not Recruiting
- The purpose of this clinical study is to assess safety and efficacy of different doses of Dysport® RU (RU= Ready to Use), a new formulation of a drug called Dysport®, which is used for the improvement in the appearance of glabellar lines (lines that appear on the forehead between the eyebrows). Additionally, the study will aim to establish the dose of Dysport® RU, which is equivalent in terms of safety and efficacy to the optimal dose of 50 U of Dysport®.
- Moderate to severe glabellar lines br>MedDRA version: 13.1 Level: LLT Classification code 10052609 Term: Glabellar frown lines System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Body processes [G] - Physical Phenomena [G01]
- Germany
- 2010-12-27
Not recruiting
- A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
- Non-Small Cell Lung Cancer;Non-Small Cell Lung Cancer;Non-Small Cell Lung Cancer;Non-Small Cell Lung Cancer
- Argentina, Austria, Brazil, Canada, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Poland, Puerto Rico, Romania, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States
- 2010-07-16
Not recruiting
- A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
- Hepatocellular Carcinoma;Hepatocellular Carcinoma;Hepatocellular Carcinoma;Hepatocellular Carcinoma
- Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Finland, France, Germany, Hong Kong, Hungary, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, New Zealand, Norway, Philippines, Portugal, Puerto Rico, Romania, Singapore, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United States
- 2010-06-02
Not Recruiting
- A PROSPECTIVE, MULTICENTER, DOUBLE-RANDOMISED, DOUBLE-BLIND, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE AS FIRST LINE THERAPY EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH GEMCITABINE, TO GEMCITABINE IN COMBINATION WITH PLACEBO, FOLLOWED AS SECOND LINE TREATMENT BY MASITINIB IN COMBINATION WITH FOLFIRI 3 VERSUS PLACEBO IN COMBINATION WITH FOLFIRI 3 IN THE TREATMENT OF PATIENTS WITH NON RESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER
- -C259 Pancreas, unspecified Pancreas, unspecified;Pancreas, unspecified
- Brazil, Bulgaria, Chile, China, Colombia, Czech Republic, Georgia, Germany, Greece, Hungary, India, Italy, Malasya, Mexico, Morocco, Peru, Philippines, Poland, Romania, Russian Federation, Singapore, Slovakia, Spain, Taiwan, Thailand, Tunisia, Ukraine, United Kindgdom
- 2016-04-20
Not Recruiting
- Prospective, randomised, double-blind trial of heparin or 0.45% saline infusion through the long line to reduce the incidence of long line sepsis in very low birth-weight infants
- Long line infections in very low birth-weight (VLBW) infants Neonatal Diseases Sepsis
- United Kingdom
- 2006-05-26